Vista normal Vista MARC Vista ISBD

Biomarkers for Huntington's Disease [electronic resource] : Improving Clinical Outcomes / edited by Elizabeth A. Thomas, Georgia M. Parkin.

Colaborador(es): Thomas, Elizabeth A [editor.] | Parkin, Georgia M [editor.] | SpringerLink (Online service)Tipo de material: Texto

TextoSeries Contemporary Clinical NeuroscienceEditor: Cham : Springer International Publishing : Imprint: Springer, 2023Edición: 1st ed. 2023Descripción: XVI, 475 p. 42 illus., 39 illus. in color. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9783031328152Tema(s): Neurosciences | Neurology | Neurophysiology | Neuropharmacology | Neuroscience | Neurology | Neurophysiology | NeuropharmacologyFormatos físicos adicionales: Printed edition:: Sin título; Printed edition:: Sin título; Printed edition:: Sin títuloClasificación CDD: 612.8 Clasificación LoC:RC321-580Recursos en línea: Libro electrónico Texto

Contenidos:

Molecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers -- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics -- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers -- MRI - non-invasive functional MRI measures -- The evolution of clinical trial methodology.-Digital biomarkers -- The future of telehealth -- Summary and future trends.

En: Springer Nature eBookResumen: Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.

Existencias ( 1 )
Notas de título ( 4 )

Existencias
Tipo de ítem	Biblioteca actual	Colección	Signatura	Copia número	Estado	Fecha de vencimiento	Código de barras
Libro Electrónico	Biblioteca Electrónica	Colección de Libros Electrónicos		1	No para préstamo

Acceso multiusuario

Huntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.

UABC ; Perpetuidad